Policies drive new drug R & D, biological products and pharmaceutical enterprises

[China Pharmaceutical network industry trends] with the official issuance of the 13th five year plan for the development of biological industry by the national development and Reform Commission, biomedicine has ushered in a new round of development opportunities Specific to the biomedical industry, it is required to achieve an industrial sales revenue of 4.5 trillion yuan by 2020, with the added value accounting for 3.6% of the national industrial added value Innovation and R & D will have an important impact on this goal On the 2017 China Pharmaceutical Innovation Summit Forum and the list of top 100 pharmaceutical enterprises' R & D strength, 4 enterprises settled in China Pharmaceutical city have entered the top 50 of 2017 China Bio pharmaceutical R & D strength list From China official account China's WeChat public issue, we learned that on September 8th -10, the 2017 China Pharmaceutical Summit Forum and the top 100 research and development list of pharmaceutical enterprises sponsored by China Pharmaceutical magazine jointly held in Chongqing, the 2017 China Pharmaceutical Research and development strength list (including the list, chemical list, Chinese Medicine list and biological medicine) was released List, brand list) and give awards and medals to the shortlisted enterprises on the spot Enterprises settled in China Pharmaceutical city - Jiangsu Taikang biomedical Co., Ltd., Taizhou mabotaco Pharmaceutical Co., Ltd., Jiangsu jindick Biotechnology Co., Ltd and Taizhou Junshi Biomedical Technology Co., Ltd have entered the top 50 of 2017 China's biomedical R & D strength ranking From the perspective of the whole market, domestic pharmaceutical investment scale and growth rate are very fast, especially in the field of biological medicine On November 29, 2016, Cinda biology announced that it had successfully completed the D round financing of 260 million US dollars (about 1.7 billion yuan) The financing amount was among the best in the whole biomedical industry of China and even in the global non IPO Financing in 2016 With the national development and Reform Commission officially printing and distributing the 13th five year plan for the development of biological industry, biomedicine has ushered in a new round of development opportunities According to the plan, during the 13th Five Year Plan period, China's biomedical industry will focus on the development of major disease chemicals, biotechnology drugs, new vaccines, new cell therapy agents and other innovative drug categories Specific to the biomedical industry, it is required to achieve an industrial sales revenue of 4.5 trillion yuan by 2020, with the added value accounting for 3.6% of the national industrial added value According to the statistics of pharmaceutical intelligence data, in 2015, CDE accepted a total of 558 biological products (calculated by acceptance number, the same below), accounting for 6.8% of the total accepted drugs; In 2016, there were 408 biological products accepted by CDE, accounting for 10.79% of the total accepted quantity Although the accepted quantity of biological products has declined, the proportion of biological products in other drugs has increased It can be seen that enterprises began to layout the biological products market (as shown in Figure 1 and figure 2) The national system of drug acceptance, approval and supervision is becoming more and more strict The decline in the acceptance of biological products is closely related to the sharp decline in the overall acceptance of all kinds of drugs in 2016 The policy urges pharmaceutical enterprises to make high-end and refined drugs in order to keep the market, and the research and development of biological products is a good choice Original title: China Pharmaceutical City 4 enterprises enter China Pharmaceutical R & D strength ranking reporter: Hu Anping, Zhu laidong, Gu Jihong seize the opportunity of pharmaceutical machinery and equipment industry, please download app (Pharma, Android version)!